ANABANAPTYSBIO, INCvs its industry peers
A metric-by-metric comparison of ANAPTYSBIO, INC against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANABThis | $1.6B#4 | — | 124.0x#6 | 6.7x#1 | 157.0%#3 | 90.9%#3 | 20.4%#1 | -103.8%#7 | — | — | 180.0%#3 | — |
| STOK | $1.8B#1 | — | 5.2x#3 | 9.8x#2 | 404.5%#2 | 92.3%#2 | -11.2%#4 | -2.0%#3 | — | — | 20.6%#5 | — |
| SEPN | $1.8B#2 | — | 4.6x#2 | 39.0x#4 | 4174.5%#1 | 31.9%#4 | -148.6%#5 | -12.6%#5 | — | — | 165.5%#4 | — |
| ANIP | — | 16.1x#2 | — | — | 43.8%#5 | 510.5%#1 | 12.6%#2 | 13.1%#1 | 16.9%#1 | — | -24.5%#6 | — |
| ETON | $1.6B#3 | — | 34.6x#5 | 20.1x#3 | 104.9%#4 | -20.4%#5 | -1.1%#3 | -9.9%#4 | -1.8%#2 | 4#1 | 220.3%#2 | — |
| DMRA | $1.5B#5 | 3.2x#1 | 2.9x#1 | — | — | -878.8%#6 | — | -40.7%#6 | — | — | 751.8%#1 | — |
| TRAX | $1.4B#6 | — | 8.3x#4 | — | — | — | — | 0.0%#2 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice